CXCL1 and cancer: Regardless of clinicopathological characteristics, significant expression differences were observed, including 10 upregulated genes (CCL4/18, CXCL1/10/11, IFNγ, IL2/6/12A, VEGFA) and 1 downregulated gene (HLA-A) in lymphocytes from malignant ascites (Figure 4).